Aegle Therapeutics
Aegle Therapeutics Corporation, a regenerative medicine company isolating extracellular vesicles ("EVs") from allogeneic bone marrow derived mesenchymal stem cells (MSCs) to treat severe dermatological conditions, including burns and epidermolysis bullosa (“EB”).
5
Funding Rounds
$14.5m
Money raised
Overview
Aegle Therapeutics Corporation, a regenerative medicine company isolating extracellular vesicles ("EVs") from allogeneic bone marrow derived mesenchymal stem cells (MSCs) to treat severe dermatological conditions, including burns and epidermolysis bullosa (“EB”).
| Name | Phone | Social networks | |
|---|---|---|---|
| Sh***** Ha***** | - | - | |
| Ev******* Ba****** | - | - | - |
| Ro**** Wi******** | - | - | - |
Funding series
Funding Series Analysis
The company Aegle Therapeutics has raised a total of $10.5m in funding over 5 rounds.
Key Insights:
- Aegle Therapeutics Series A round, September 2020: $6.5m
- Aegle Therapeutics Funding Round 2020: $4m
- Aegle Therapeutics Series A Funding Round January 2020: $4m
Aegle Therapeutics Series A round, September 2020
$6.5m
Aegle Therapeutics Funding Round 2020
$4m
Aegle Therapeutics Corp funding round, January 2020
$
Aegle Therapeutics Series A Funding Round January 2020
$4m
Industries
Aegle Therapeutics is active in the following industries: